Similar articles for PMID: 22667993

Year	Number of Results
1994	1
2001	1
2002	3
2003	2
2004	2
2005	6
2006	1
2007	2
2008	3
2009	9
2010	5
2011	13
2012	20
2013	17
2014	11
2015	20
2016	13
2017	11
2018	18
2019	11
2020	10
2021	12
2022	8
2023	2
2024	0

1

Tumor-stromal interactions in lung cancer: novel candidate targets for therapeutic intervention.

El-Nikhely N, Larzabal L, Seeger W, Calvo A, Savai R. El-Nikhely N, et al. Expert Opin Investig Drugs. 2012 Aug;21(8):1107-22. doi: 10.1517/13543784.2012.693478. Epub 2012 Jun 6. Expert Opin Investig Drugs. 2012. PMID: 22667993 Review.

2

The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets.

Wood SL, Pernemalm M, Crosbie PA, Whetton AD. Wood SL, et al. Cancer Treat Rev. 2014 May;40(4):558-66. doi: 10.1016/j.ctrv.2013.10.001. Epub 2013 Oct 15. Cancer Treat Rev. 2014. PMID: 24176790 Review.

3

New molecular targeted therapies integrated with radiation therapy in lung cancer.

Provencio M, Sánchez A, Garrido P, Valcárcel F. Provencio M, et al. Clin Lung Cancer. 2010 Mar 1;11(2):91-7. doi: 10.3816/CLC.2010.n.012. Clin Lung Cancer. 2010. PMID: 20199974 Review.

4

The Microenvironment of Lung Cancer and Therapeutic Implications.

Mittal V, El Rayes T, Narula N, McGraw TE, Altorki NK, Barcellos-Hoff MH. Mittal V, et al. Adv Exp Med Biol. 2016;890:75-110. doi: 10.1007/978-3-319-24932-2_5. Adv Exp Med Biol. 2016. PMID: 26703800 Review.

5

Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout.

Favoni RE, Alama A. Favoni RE, et al. Drug Discov Today. 2013 Jan;18(1-2):11-24. doi: 10.1016/j.drudis.2012.07.011. Epub 2012 Aug 4. Drug Discov Today. 2013. PMID: 22885521 Review.

6

Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents.

Gridelli C, Rossi A, Maione P. Gridelli C, et al. Oncogene. 2003 Sep 29;22(42):6629-38. doi: 10.1038/sj.onc.1206957. Oncogene. 2003. PMID: 14528288 Review.

7

Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.

Barlési F, Tchouhadjian C, Doddoli C, Villani P, Greillier L, Kleisbauer JP, Thomas P, Astoul P. Barlési F, et al. Fundam Clin Pharmacol. 2005 Jun;19(3):385-93. doi: 10.1111/j.1472-8206.2005.00323.x. Fundam Clin Pharmacol. 2005. PMID: 15910663

8

New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.

Crawford J. Crawford J. J Natl Compr Canc Netw. 2003 Jan;1 Suppl 1:S78-86. J Natl Compr Canc Netw. 2003. PMID: 19795580 Review.

9

Targeted therapy of non-small-cell lung carcinoma.

Tiwari D, Brodie SA, Brandes JC. Tiwari D, et al. Ther Adv Respir Dis. 2012 Feb;6(1):41-56. doi: 10.1177/1753465811404590. Epub 2011 Jul 5. Ther Adv Respir Dis. 2012. PMID: 21730004 Free article. Review.

10

Inhibition of platelet-derived growth factor receptor α by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer.

Laing N, McDermott B, Wen S, Yang D, Lawson D, Collins M, Reimer C, Hall PA, Andersén H, Snaith M, Wang X, Bedian V, Cao ZA, Blakey D. Laing N, et al. Mol Pharmacol. 2013 Jun;83(6):1247-56. doi: 10.1124/mol.112.084079. Epub 2013 Apr 4. Mol Pharmacol. 2013. PMID: 23558446

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

170 results

Results by year